文献速递胸部肿瘤

可切除非小细胞肺癌常见分子改变预后影响及对第十版TNM分期的启示

The Prognostic Impact of Common Molecular Alterations in Resected Lung Adenocarcinoma and Implications for the Tenth Edition TNM Classification.
PubMed 文献 · J Thorac Oncol · 2026-06-05

本研究纳入2008至2021年诊断的5839例患者,分析TP53、EGFR、KRAS突变及ALK融合在特定分期的预后价值。结果显示I期EGFR突变者OS更优,I期TP53或KRAS突变者OS更差,III-IV期ALK融合者OS更优,提示TP53、KRAS和ALK改变可能修正现有分期。

要点

  • I期EGFR突变者OS显著更优,I期TP53或KRAS突变者OS显著更差。
  • III-IV期ALK融合者OS与II期相当,提示降期可能。
  • I期TP53或KRAS突变者OS与IB期相当,提示升期可能。

核心结论

  • 肺癌常见分子改变在特定分期具有预后价值,TP53、KRAS和ALK改变可能修正现有分期系统。

研究设计与样本

  • 回顾性队列研究,纳入2008至2021年诊断的5839例患者,分析TP53、EGFR、KRAS突变及ALK融合。

主要发现

  • EGFR突变2304例(54.7%),TP53突变692例(29.9%),KRAS突变287例(6.8%),ALK融合243例(4.6%)。
  • I期EGFR突变者OS显著更优(HR=0.59),I期TP53突变者OS显著更差(HR=2.49),I期KRAS突变者OS显著更差(HR=1.57)。
  • III-IV期ALK融合者OS显著更优。
  • I期TP53或KRAS突变者OS与IB期相当,III-IV期ALK融合者OS与II期相当。

临床怎么用

  • 对于I期患者,TP53或KRAS突变可考虑升期,EGFR突变可考虑降期。
  • 对于III-IV期ALK融合患者,可考虑降期至II期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Whether gene mutations can be integrated into the forthcoming tenth edition TNM staging system is of great interest. We aimed to validate the prognostic impact of major driver genes and to investigate their potential for refining the TNM framework. METHODS: Eligible patients were diagnosed between 2008 and 2021. The analysis was restricted to the following four genes: TP53 mutations ("oncogenic/likely oncogenic" annotated by the OncoKB database), EGFR mutations (L858R, exon 19 deletion), KRAS mutations (codons 12, 13, or 61), and ALK fusions. The stage-specific prognostic value of these mutations was determined using the Kaplan-Meier method. The independent prognostic value of these alterations across TNM stages was assessed using Cox proportional hazards regression models. RESULTS: A total of 5839 patients were included (ALK, n = 5303; KRAS, n = 4225; EGFR, n = 4212; TP53, n = 2312). EGFR mutations were found in 2304 (54.7%), TP53 mutations in 692 (29.9%), KRAS mutations in 287 (6.8%), and ALK fusions in 243 (4.6%). Overall survival (OS) was significantly better among patients with stage I EGFR-mutated tumors and stages III to IV ALK fusion-positive tumors, whereas patients with stage I TP53-mutated and KRAS-mutated tumors had significantly worse OS. Multivariable analyses confirmed the OS associations with TP53-mutated tumors (stage I hazard ratio [HR] = 2.49), KRAS-mutated tumors (stage I HR = 1.57), and EGFR-mutated tumors (stage I HR = 0.59). In the "upstaging/downstaging" analysis, patients with TP53- or KRAS-mutated stage IA disease exhibited OS comparable to stage IB, supporting an "upstaging" potential. Conversely, patients with stage III to IV ALK fusions had OS comparable to that of stage II, supporting a "downstaging" potential. CONCLUSIONS: This study suggests that common molecular alterations in lung cancer exhibit prognostic value within specific stages, and, notably, TP53, KRAS, and ALK alterations hold the potential to modify the current staging system. These findings provide a valuable reference for the forthcoming tenth edition TNM staging system.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Tang H, Deng C, Cao H, et al. The Prognostic Impact of Common Molecular Alterations in Resected Lung Adenocarcinoma and Implications for the Tenth Edition TNM Classification. J Thorac Oncol. 2026. PMID: 42250800. doi:10.1016/j.jtho.2026.103965

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。